Selank

Selank exerts its reported effects through a combination of mechanisms that bridge immunological and central nervous system signaling. As an analog of tuftsin, the peptide retains affinity for tuftsin-recognizing sites on monocytes, macrophages, and microglia, where engagement has been associated with modulation of phagocytic activity and of cytokine release. Russian and collaborating investigators have reported that selank alters the balance of pro-inflammatory and anti-inflammatory cytokines in plasma and central nervous system tissue, with reductions in interleukin-6 frequently described.

Within the central nervous system, preclinical work has reported modulation of GABAergic transmission, with observations consistent with potentiation of GABA-A receptor function in hippocampal and cortical preparations contributing to the anxiolytic-like behavioral profile. Additional reports describe upregulation of brain-derived neurotrophic factor (BDNF) expression in hippocampal tissue, modulation of serotonergic and noradrenergic turnover, and inhibition of enkephalin-degrading enzymes, which together provide a candidate framework for the observed effects on anxiety-like behavior and on learning and memory in rodent paradigms. The relative contribution of each pathway to the in vivo phenotype remains an open question in the published literature.

The development of selank arose from a long-standing Russian scientific program on short regulatory peptides initiated at the Institute of Molecular Genetics of the Russian Academy of Sciences under the direction of Nikolai Myasoedov, in collaboration with the V.V. Zakusov Research Institute of Pharmacology. The conceptual starting point was the endogenous tetrapeptide tuftsin, originally described in the 1970s as an immunomodulatory fragment of immunoglobulin G. Tuftsin itself is rapidly degraded in vivo, and the design of selank addressed this limitation by appending the Pro-Gly-Pro tripeptide, a motif known to stabilize short peptides against aminopeptidase action.

Through the 1990s, Russian groups characterized selank in preclinical models of anxiety, learning, and immune function. Reports by Ostrovskaya, Levitskaya, Seredenin and colleagues described anxiolytic-like effects in elevated plus maze and conflict paradigms, modulation of conditioned avoidance and passive avoidance learning, and effects on monoaminergic systems. Parallel work examined immunological endpoints consistent with the tuftsin-derived design, including effects on phagocytic activity and on cytokine balance.

Clinical research conducted predominantly in Russia in the 2000s and 2010s examined intranasal formulations in cohorts with generalized anxiety disorder and neurasthenia. Reports from Zozulia, Medvedev and colleagues at Russian clinical centers described anxiolytic observations and tolerability in small to moderate cohorts. Mechanistic work in this period extended to studies of BDNF expression in hippocampal tissue, of enkephalin metabolism, and of interleukin-6 signaling. The compound has been registered for clinical use in the Russian Federation but has not entered Western regulatory development, and independent replication of the key behavioral and clinical observations by non-Russian-affiliated groups remains limited. The published evidence base should be evaluated with this geographic concentration in mind. Selank nonetheless remains an interesting reference compound in academic research on tuftsin-like signaling and on short, stabilized neuropeptides.